Actimad-A Phase I/III Study Completed by Actinium Pharmaceuticals

Actinium Pharmaceuticals, Inc. a biotechnology business enterprise focused on producing innovative, alpha particle radiotherapy specified cancer therapies dealing with major unmet medical needs, in these days announced that it has treated successfully the first cohort of affected individuals in a Phase I/II study of Actimab-A in Acute Myeloid Leukemia (AML) clinical trial. Affected individuals were really treated at Memorial Sloan Kettering Cancer Center in New York City.

Affected individuals enrolled to begin with cohort within this ongoing trial were really treated with a dose level of 0.5 microCi/kg of Actimab-A, with a couple of consecutive doses given a week apart. Actimab-A therapy includes isotope Actinium 225 linked with the anti-CD33 monoclonal antibody lintuzumab (HuM195).

Dr. Dragan Cicic, the CEO of Actinium Pharmaceuticals said: "As we constantly attain our affirmed milestones, finishing of the first cohort brought us an additional step closer towards the Phase II segment of the trial.". "We are essentially anticipating accelerated accrual and sensible finishing of the current test and proceeding into Phase II as intended."